Introduction
Travelers' diarrhea (TD) is the most common travel-related illness, affecting up to 70% of travelers to certain destinations. 1 Its etiology is predominantly bacterial, representing approximately 80% to 90% of illnesses, 1 
including diarrheagenic
Escherichia coli, Salmonella, Shigella and Campylobacter species, but it can also be caused by parasites, such as Giardia and Cryptosporidium, and viruses, such as norovirus. 1, 2 Opportunity costs, changes to trip itineraries and seeking medical care abroad are just some of the consequences that can result from a bout of TD. Emerging data have affected the recommendations for the prevention and treatment of TD, resulting in the publication of a set of guidelines for the condition in a 2017 supplement to the Journal of Travel Medicine. 3 As highly accessible experts in pharmacotherapy, pharmacists are well positioned to address travel-related concerns, particularly regarding TD, at both the prescription counter and over-the-counter (OTC) aisle. Pharmacists can draw from the guidelines to ensure patients are counselled on safe and appropriate antibiotic therapy during international travel and can direct patients to important nonprescription products supported by the guidelines and provide advice on their safe and effective use. This article summarizes the key recommendations from the 2017 guidelines of interest to practising community pharmacists. Readers requiring additional information are encouraged to consult the full guideline publication.
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Development of the guidelines
The International Society of Travel Medicine (ISTM) used a panel of experts with relevant experience in the disease's management to formulate the
Guidelines for the Prevention and Treatment of Travelers' Diarrhea: A Graded Expert Panel
Report. Despite ISTM not having a designated process and resources to develop clinical practice guidelines, the panel members attempted to follow the Institute of Medicine guideline standards and Grades of Recommendations, Assessment, Development and Evaluation (GRADE) framework. 3 Each recommendation in the guideline underwent the same procedures: "Recommendation formulation [with a threshold of 80% agreement among panel members], grading the quality of evidence in terms of the confidence in the estimates of the efficacy and harms of the intervention and grading the strength of the recommendation based on the balance of harms and benefits and knowledge of the values and preferences of the travelers. " 3 Prior to publication, the manuscript was peer-reviewed by experts in infectious diseases and travel medicine who were not involved in the development of the guidelines. Readers seeking additional details on guideline development are referred to the Journal of Travel Medicine.
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TD definitions
TD has previously been classified quantitatively, based on the number of loose bowel movements experienced in a day (e.g., mild = 1-2 stools/ 24 hours, moderate = 3-5 stools/24 hours and severe = 6-9 stools/24 hours). 4, 5 Classification is now qualitative, based on the functional impact TD has on the patient and his or her ability to participate in activities planned during travel (Table 1) . Patients should be counselled on these definitions in order to properly recognize when to begin self-treatment and which treatments should be used (discussed below). It is important PRaCtiCe guideLiNes to emphasize the "functional impact" when educating, so that travelers can recognize the form of illness they are experiencing. For example, 1 episode with severe fever, cramping and bloody stools may be more impairing than 4 unformed stools without any other symptoms. Furthermore, as severe dysentery TD is typically accompanied by a fever, and traveling patients will likely not be carrying a thermometer, pharmacists should discuss its symptomatology so that patients can recognize this severe form of illness. Pharmacists should advise patients to seek medical assessment for TD lasting longer than 14 days, as persistent diarrhea may be associated with a higher frequency of certain bacteria, protozoal pathogens or other noninfectious conditions that may require targeted diagnosis and treatment.
TD prophylaxis
Antimicrobial resistance is a serious global health issue, necessitating the judicious use of antibiotics. For most travelers, antibiotics should not routinely be used for TD prophylaxis. However, antimicrobial prophylaxis can be considered for patients at a high risk for complications secondary to TD, such as those who have a clinically significant history of potential additional morbidity following an enteric infection (e.g., inflammatory bowel disease, reactive arthritis) or a chronic illness that predisposes them to TD (e.g., achlorhydria, gastrectomy) or its complications (e.g., immunocompromised, diabetes, renal dysfunction). 3 Other individuals who may be considered for TD prophylaxis include travelers who cannot afford to become sick with TD due to occupation or itinerary reasons (e.g., athlete in competition, musician, politician). 3 Because of the rapid efficacy of TD selftreatment and increasing rates of antimicrobial resistance, individual risk-benefit assessments and appropriate counselling must be performed before considering prophylaxis.
TD prophylaxis can be employed without antibiotics through the use of bismuth subsalicylate. Doses of 2.1 g/day or 4.2 g/day in 4 divided doses (with meals and bedtime) in either the liquid or tablet form have been studied and demonstrated a consistent protective effect against TD, upwards of 60%. [6] [7] [8] Despite robust evidence, its adverse effects, most commonly including black tongue and stools and least commonly being tinnitus, can be undesirable for traveling patients. 6 In addition, its contraindications in pediatric, pregnant, aspirin-allergic and aspirin-taking patients limit its use in the prevention of TD, and its frequent dosing may also affect adherence. If antibiotic prophylaxis is warranted in a traveling patient, rifaximin is advised, 3 
Practice guidelines trials and thus may represent the best solution for short-term protection when needed. 15 Although they have long been prescribed for prophylaxis, fluoroquinolones are no longer recommended for prophylaxis of TD because of the emerging resistance of enteric pathogens. The use of fluoroquinolones exposes patients to potential harm to the peripheral and central nervous system, tendons, muscles and joints, as well as the possibility of Clostridium difficile-associated diarrhea. Therefore, based on its highrisk and low-benefit profile, the guidelines do not recommend the use of fluoroquinolones in TD prophylaxis. In addition, recommendations regarding azithromycin's prophylactic use have not been determined in the 2017 guidelines. 3 Pharmacists are reminded to encourage patients to also practise food and water precautions to minimize their risk of exposure to TD-causing organisms. Frequent handwashing, especially prior to meals, with warm soap and water or the use of an alcohol-based hand sanitizer with ≥60% alcohol is recommended. 16 It is safest to eat food that is fully cooked and served hot, as raw or undercooked meals containing meat and fish are likely to be contaminated. 16 When selecting foods to eat abroad where hygiene and sanitation are inadequate or unknown, travelers should also be advised to avoid unpasteurized fruit juices, milks or cheeses, produce washed in local water sources and raw fruits that are unpeeled (e.g., strawberries), as opposed to fruits that are peeled by the traveler (e.g., bananas and mangoes). 16 Commercially bottled water with a preserved seal should be recommended for drinking, preparing food and beverages, making ice and brushing teeth.
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Therapy for mild TD
Most cases of TD can be classified as mild: otherwise tolerable, nondistressing and does not interfere with planned activities. Because of increasing antimicrobial resistance and concerns regarding multidrug-resistant organisms, antibiotic conservation is advised. Therefore, antibiotic treatment is not recommended in patients with mild TD. Instead, supportive measures such as oral rehydration therapy and nonantibiotic, antimotility drugs such as loperamide can be used. Loperamide's use in mild TD has been shown to decrease the duration of diarrhea and the frequency of passing unformed stools. [17] [18] [19] Although previously discouraged for TD treatment because of its antimotility effects and concerns about potential retention of pathogens in the gut, a number of observational studies support the safe and effective use of loperamide in the treatment of mild TD. 20, 21 Loperamide and bismuth subsalicylate are the 2 OTC products with the most supportive evidence, with stronger evidence favoring loperamide over bismuth subsalicylate. 17 Other agents, such as activated charcoal or dimenhydrinate, are not recommended. Although loperamide is the recommended first-line agent, patients should be informed that if the diarrhea worsens or is accompanied by moderate-severe or invasive symptoms (1 or more of fever, moderate to severe abdominal pain or bloody diarrhea), then antibiotics should be used ( 32 These resistance rates and safety concerns regarding their potential for intestinal microbiota imbalance and musculoskeletal consequences have resulted in a nonunanimous recommendation by the guideline's expert panel.
Canadian readers should note that while ofloxacin is a fluoroquinolone listed for TD treatment in the guidelines, it is not currently marketed in an oral formulation in Canada. As an alternative to fluoroquinolones, azithromycin may also be considered for moderate TD, as studies indicate there is no significant difference in efficacy between azithromycin and fluoroquinolones. 9 However, it should be noted that as the TD classification changes from moderate to severe, the 2017 guidelines prefer azithromycin as the primary treatment option (discussed below). 3 Apart from concerns in Nepal, azithromycin has limited global resistance, and despite requiring increased concentrations to inhibit enterotoxigenic and enteroaggregative E. coli (ETEC and EAEC, respectively), this has not yet resulted in documented clinical failure. It also has a much more tolerable safety profile compared with fluoroquinolones, with the exception of nausea and vomiting, particularly when the single dose of 1000 mg is ingested. However, both azithromycin and fluoroquinolones potentially expose certain patients to the risk of QT prolongation and must be carefully considered for patients at risk of this, including those with a QTc interval >500 ms, advanced age, female sex and concomitant QTc-prolonging medications, such as some antidepressants and antipsychotics. 33 Finally, the guidelines also recommend rifaximin as another alternative for moderate TD. However, as the only rifaximin products currently licensed in Canada are 550 mg tablets, and the splitting of tablets is not recommended by the manufacturer, 34 product availability prevents Canadian patients from accessing the recommended treatment dose of 200 mg 3 times daily unless they purchase it abroad. As a poorly absorbed antibiotic, it has an excellent safety profile and limited global resistance rates; however, its use is cautioned for travel to regions with a high risk of invasive pathogens, such as Campylobacter, Shigella and Salmonella, because of its poor clinical success against these species.
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A recent trial evaluating single high-dose rifaximin (1650 mg) in combination with loperamide was found to be comparable to single-dose levofloxacin (500 mg) and azithromycin (500 mg), with clinical cures of about 14 hours. 37 As mentioned previously, loperamide may be used either in combination therapy with antibiotics or as monotherapy for moderate TD. Its quick onset when used with antibiotics provides symptomatic relief in addition to curative treatment. Concerns about adverse effects, including disruption of the diversity of intestinal flora and ESBL-PE colonization, surrounding combination therapy remain unsubstantiated. Despite the apprehension of increasing a TD patient's exposure to pathogens when motility is slowed, Practice guidelines loperamide's studied effectiveness has led to its safe recommendation as a solo therapy in nonsevere TD. 3 Other than constipation, which may occur from patients taking doses at too frequent intervals (patients should be advised that it has an onset of action of up to 1-2 hours), it is a well-tolerated agent. Combination therapy with loperamide has consistently demonstrated an advantage in time to clinical cure compared with antibiotics alone.
Therapy for severe TD
Severe TD includes both nondysenteric watery diarrhea affecting a traveler's quality of life and dysentery. Both presentations are important to consider and discern as this guides the antibiotic management options. The main distinction between the 2 types of severe diarrhea is the presence of blood in the stool (possibly accompanied by fever and/or abdominal pain), as this depicts the hallmark clinical presentation of dysentery.
bOX 1 Key points regarding travelers' diarrhea for pharmacists
The release of the 2017 guidelines for the prevention and treatment of travelers' diarrhea has resulted in significant changes in the management of travelers' diarrhea, many of which affect community pharmacy practice. The key points of interest to pharmacists are summarized here:
• Classification of TD  TD severity should be based on a patient's self-determination:  Mild: Tolerable, nondistressing and does not interfere with planned activities  Moderate: Distressing or interfering with planned activities  Severe: Incapacitating or completing stopping all planned activities, including dysentery and nondysentery presentations  Persistent: Diarrhea lasting ≥2 weeks
• TD prophylaxis  Prophylaxis is not routinely used but can be considered for patients at high risk of health-related complications secondary to TD such as:  prior clinically significant history of potential additional morbidity following an enteric infection (e.g., inflammatory bowel disease, reactive arthritis) and  chronic illness that predisposes patient to TD (e.g., achlorhydria, gastrectomy) or its complications (e.g., immunocompromised, diabetes, renal dysfunction).  Prophylaxis may be considered for travelers who cannot afford to become sick with TD because of their occupation or itinerary reasons (e.g., athlete in competition, musician, politician).  Bismuth subsalicylate may be considered for most travelers as prophylaxis.  If antibiotic prophylaxis is indicated, rifaximin is the recommended agent.
• Mild TD  Patients can use loperamide for the treatment of mild TD to decrease the duration of diarrhea and frequency of passing unformed stool.
• Moderate TD  Functional impairment and itinerary changes are the main factors to consider when using self-determining to use antibiotics for moderate TD.  Antibiotic treatment options available in Canada are azithromycin and fluoroquinolones (when traveling outside of Southeast Asia).  Because of emerging global resistance and efficacy, pharmacists may notice a shift in prescribing practices, in which azithromycin is used as the first-line treatment for both moderate and severe TD.  Loperamide can be used either alone or as an adjunct to antibiotics.
• Severe TD  Travelers should be educated on how to self-diagnose dysentery (presence of blood in the stool, possibly accompanied by fever and/or abdominal pain) to determine appropriate treatment measures.  Antibiotics should be used for severe travelers' diarrhea, both dysentery and nondysentery, with azithromycin being the antibiotic of choice.  Loperamide may also be used as an adjunct to azithromycin, in the absence of dysentery.
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For both nondysenteric and dysenteric TD, azithromycin is the preferred agent because of its low global resistance against invasive pathogens and tolerable safety profile. [38] [39] [40] [41] A single-dose antibiotic regimen can be tried initially and continued daily for up to 3 days if symptoms are not resolved within 24 hours. Therefore, pharmacists should ensure patients are provided sufficient antibiotics to allow for both a single dose and a complete 3-day regimen. Fluoroquinolones may be used to treat severe, nondysenteric TD, provided the traveler is not going to Southeast or South Asia (due to Campylobacter resistance) and a proper riskbenefit assessment has been completed regarding its safety profile. Rifaximin may also be used to treat severe, nondysenteric TD, provided the traveler is not going to a region that has a high risk of invasive pathogens, due to the drug's lack of efficacy against them. However, as mentioned, this product is not available in a suitable strength in Canada and would need to be acquired by patients abroad, limiting its applicability to Canadian travelers. As with moderate diarrhea, combination therapy consisting of antibiotics with loperamide improves time to clinical cure compared with antibiotics alone. However, the combination should not be employed when dysentery is present.
Additional consensus statements of interest to pharmacists
Despite their appeal, prebiotics and probiotics are not currently recommended to prevent or treat TD. More research is needed to determine their use in TD, as questions remain regarding formulation, dosing, strain or combination for the right condition or individual, knowledge of the host microbiome and mechanisms of action. In addition, there is an emerging concern involving the association between travel, the use of antibiotics in TD and the colonization of multidrug-resistant organisms. Carriage is mostly transient but can be persistent 1 year posttravel in approximately 10% of travelers and transmitted to household contacts. 3 Pharmacists should discuss with patients this multidimensional risk regarding travel, TD and the use of antibiotics abroad. Female patients presenting with a urinary tract infection with recent travel should have a urine culture to ensure appropriate antibiotic choice.
Changes to the definitions of illness severity to be largely based on its functional impact on patients (and treatment recommendations based on these symptoms) make it increasingly important for pharmacists to have shared decision-making discussions with patients, considering their individual risk of TD or its complications, their itinerary and goals of their travel and their ability to cope with symptoms abroad. As patients will often need to make symptom assessment and treatment decisions without pharmacist assistance abroad, these discussions at the time of dispensing are especially important to ensure optimal outcomes. ■ Key points for pharmacists related to the prevention and treatment of TD are summarized in Box 1 and the provided infographic, with additional resources that may be of interest provided in Box 2.  Readers should note that information presented in this guideline related to definitions of TD and management options based on the number of loose stools has been redefined in more recent guidelines; however, the document still provides valuable guidance on symptom management. • Pharmacy5in5 TD Infographic (https://uwaterloo.ca/pharmacy/sites/ca.pharmacy/files/uploads/files/tdinfographic.pdf)  Pharmacy5in5 is a free online learning platform designed by pharmacists for pharmacists and pharmacy technicians.
Pharmacists interested in testing their TD knowledge are encouraged to complete the module on TD. Treatment during the trip 3 
